Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group

Leukemia & Lymphoma
Eva KimbyNordic Lymphoma Group

Abstract

The purpose of this phase II randomized trial was to evaluate the effect and safety of interferon-alpha2a (IFN) in combination with extended dosing rituximab in patients with symptomatic, advanced indolent lymphoma responding to a standard single course of rituximab. Totally 123 patients were treated with rituximab 375 mg/m2 once weekly for 4 weeks leading to 14 complete response (CR; 11%), 56 partial response (PR; 46%), and 13 minor responses (MR; 11%). Patients achieving either PR or MR were randomized to four more infusions of rituximab alone (n = 36) or in combination with five weeks of IFN (n = 33), with an overall response rate (CR + PR) of 78% and 94%, respectively. Significantly more patients in the combination arm improved their response from PR/MR to CR (P < 0.05) and more maintained their responses for > or = 24 months (72% versus 50%), respectively. Overall, 26 out of the 52 patients who achieved CR underwent minimal residual disease (MRD) evaluation. Totally 17 of these (65%) achieved MRD negativity, 14 of whom remain in CR after 4.8 years' follow-up. The addition of IFN to rituximab was generally safe, but reversible thrombocytopenia and neutropenia were noted in one and six patients, respectively, requiring a red...Continue Reading

References

Oct 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C J GallagherT A Lister
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Oct 28, 1998·The Journal of Clinical Investigation·F FaisN Chiorazzi
Aug 12, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L D PiroV Jain
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N L HarrisC D Bloomfield
Jul 1, 2004·Blood·Guillaume CartronPhilippe Solal-Celigny
Nov 19, 2004·The New England Journal of Medicine·Sandeep S DaveLouis M Staudt
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S CzuczmanS H Bernstein
Feb 3, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A Z S RohatinerT A Lister
Aug 2, 2005·Cancer Treatment Reviews·Eva Kimby
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang HiddemannMichael Unterhalt
Apr 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael HeroldUNKNOWN East German Study Group Hematology and Oncology Study

❮ Previous
Next ❯

Citations

Jan 29, 2011·Cancer Metastasis Reviews·Roch HouotRonald Levy
Jan 27, 2011·Cancer Metastasis Reviews·Riad Abès, Jean-Luc Teillaud
Sep 13, 2011·Current Hematologic Malignancy Reports·Roswitha Forstpointner, Martin Dreyling
Jul 26, 2012·Blood Cancer Journal·B E WahlinE Kimby
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Jul 23, 2013·PloS One·Dongsheng XuLuwen Zhang
May 31, 2012·Immunotherapy·Holbrook E KohrtJoshua Brody
May 7, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L ArcainiA Pulsoni
Oct 30, 2009·Leukemia & Lymphoma·Peter McLaughlin, Stefano Sacchi
Feb 21, 2009·Leukemia & Lymphoma·Kristin FeuerleinMichele Ghielmini
Nov 1, 2008·Clinical Lymphoma & Myeloma·Mathias Rummel
May 16, 2015·Cell·David J DiLillo, Jeffrey V Ravetch
Jun 21, 2015·Trends in Immunology·Frederick Arce Vargas, Sergio A Quezada
Aug 2, 2005·Cancer Treatment Reviews·Eva Kimby
Aug 11, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giovanni MartinelliMichele Ghielmini
Feb 18, 2011·The Cochrane Database of Systematic Reviews·Jasvinder A SinghRachelle Buchbinder
Jun 7, 2018·Oncoimmunology·Elena García-MartínezLorenzo Galluzzi
Oct 5, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandra LockmerEva Kimby
Feb 9, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandra LockmerEva Kimby
Sep 21, 2013·International Journal of STD & AIDS·Victor MinichielloRafat Hussain
May 19, 2019·Blood·Emanuele ZuccaUNKNOWN Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group
Aug 20, 2019·British Journal of Haematology·Sandra LockmerEva Kimby
Sep 5, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Joseph M TuscanoEdward M Newman
Apr 27, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Björn Engelbrekt WahlinEva Kimby

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.